Elsevier

Kidney International

Volume 65, Issue 5, May 2004, Pages 1544-1547
Kidney International

Renal Participants
Aberrant glycosylation in IgA nephropathy (IgAN)

https://doi.org/10.1111/j.1523-1755.2004.05407.xGet rights and content
Under an Elsevier user license
open archive

Aberrant glycosylation in IgA nephropathy (IgAN). Immunoglobulin A nephropathy (IgAN) patients exhibit circulating IgA1 with reduced galactose (Gal) and/or sialic acid (Neu5Ac) and increased exposure of N-acetylgalactosamine (GalNAc). These IgA glycoforms fix complement and in mesangial cells regulate integrin expression, enhance nitric oxide synthase (NOS) activity, decrease endothelial growth factor synthesis, meanwhile depressing proliferation and increasing apoptotis. Drugs can be targeted to the effects enhanced by aberrantly glycosylated IgA1 on mesangial cells. Recent data suggest that aberrant IgA1 glycosylation may modulate clinical expression and progression of IgAN.

Keywords

IgA nephropathy
aberrantly glycosylated IgA
pathogenesis of glomerular diseases

Cited by (0)

1

Participant and speaker.